ArticleOncogene2005
Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Assessment of the carcinogenic potential of particulate matter generated from 3D printing devices in Balb/c 3T3-1-1 cells.Scientific reports · 2024Article
- Ran GTPase and Its Importance in Cellular Signaling and Malignant Phenotype.International journal of molecular sciences · 2023Review
- Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass.Scientific reports · 2021Article
- Synergistic AHR Binding Pathway with EMT Effects on Serous Ovarian Tumors Recognized by Multidisciplinary Integrated Analysis.Biomedicines · 2021Article
- A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.International journal of molecular sciences · 2021Article
- The Clinical Significance and Potential Molecular Mechanism of Upregulated CDC28 Protein Kinase Regulatory Subunit 1B in Osteosarcoma.Journal of oncology · 2021Article
- Ran GTPase: A Key Player in Tumor Progression and Metastasis.Frontiers in cell and developmental biology · 2020Review
- Ran promotes membrane targeting and stabilization of RhoA to orchestrate ovarian cancer cell invasion.Nature communications · 2019Article
- Function of the macrophage-capping protein in colorectal carcinoma.Oncology letters · 2017Article
- CKS Proteins Promote Checkpoint Recovery by Stimulating Phosphorylation of Treslin.Molecular and cellular biology · 2017Article
- Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway.Scientific reports · 2016Article
- Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes.G3 (Bethesda, Md.) · 2016Article
- Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival.Journal of cancer research and clinical oncology · 2016Article
- Article
- Article
- Cks1: Structure, Emerging Roles and Implications in Multiple Cancers.Journal of cancer therapy · 2013Article
- Cks1 enhances transcription efficiency at the GAL1 locus by linking the Paf1 complex to the 19S proteasome.Eukaryotic cell · 2013Article
- curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome.Database : the journal of biological databases and curation · 2013Article
- Article
- Changes in gene expression and cellular architecture in an ovarian cancer progression model.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumors of low malignant potential (LMP) represent 20% of epithelial ovarian cancers (EOCs) and are associated with a better prognosis than the invasive tumors (TOV). Defining the relationship between LMPs and TOVs remains an important goal towards understanding the molecular pathways that contribute to prognosis, as well as providing molecular markers, for these EOCs. To this end, DNA microarray analyses were performed either in a primary culture or a tumor tissue model system and selected candidate genes showing a distinctive expression profile between LMPs and TOVs were identified using a class prediction approach based on three statistical methods of analysis. Both model systems appear relevant as candidate genes identified by either model allowed the proper reclassification of samples as either LMPs or TOVs. Selected candidate genes (CAS, CCNE1, LGALS8, ITGbeta3, ATP1B1, FLIP, KRT7 and KRT19) were validated by real-time quantitative PCR analysis and show differential expression between LMPs and TOVs. Immunohistochemistry analyses showed that the two tumor classes were distinguishable by their expression of CAS, TNFR1A, FLIP, CKS1 and CCNE1. These results define signature patterns for gene expression of LMPs and TOVs and identify gene candidates that warrant further study to deepen our understanding of the biology of EOC.
Indexed as
Identifiers
15940270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.